Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements
Tarsus Pharmaceuticals, Inc. (TARS) reported trailing twelve-month revenue of $606.3M (up 105.2% year on year) and net income of -$46.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $56.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TARSTarsus Pharmaceuticals, Inc.Follow TARS — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 57.0 | 25.8 | 17.4 | 183.0 | 451.4 | 606.3 | |
| Gross profit | — | 24.9 | 15.9 | 170.1 | 420.7 | 565.6 | |
| Research & development | 41.7 | 42.6 | 50.3 | 53.4 | 64.3 | 87.7 | |
| Operating income | -12.2 | -62.7 | -143.2 | -120.6 | -71.0 | -48.5 | |
| Pre-tax income | -13.8 | -62.1 | -135.9 | -115.6 | -64.4 | -39.3 | |
| Income tax | 0.1 | -0.0 | 0.0 | 0.0 | 2.1 | 7.1 | |
| Net income | -13.8 | -62.1 | -135.9 | -115.6 | -66.4 | -46.5 | |
| Diluted EPS ($) | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -1.08 | |
| Diluted shares (mn) | 20.6 | 24.6 | 29.4 | 37.6 | 41.8 | — |
USD millions · SEC XBRL
Tarsus Pharmaceuticals, Inc. — questions
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- $606.3M over the twelve months to 2026-06-30, up 105.2% year on year, from its 10-Q and 10-K filings.
- What is Tarsus Pharmaceuticals, Inc.'s net income?
- -$46.5M over the twelve months to 2026-06-30.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- $56.0M over the twelve months to 2026-06-30.
- What are Tarsus Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.08 over the twelve months to 2026-06-30.
Every figure on this page comes from Tarsus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.